OV Precision: Study Examining the Benefit of a Tumor- and Patient-specific Cancer Therapy

The long-term goal of this research project is to demonstrate whether HRD negative (HPDneg) patients benefit when additional multi-modal biological tumor information is incorporated into the molecular tumor board (mTB) treatment recommendation process.

Inclusion Criteria: * Age ≥ 18 years * Newly diagnosed EOC (adenocarcinoma of the ovary, peritoneum, and fallopian tube) and carcinosarcoma patients with a suspected FIGO Stage III and IV * No immediate need of systemic or surgical treatment at time of and until 2 weeks after diagnosis * Envisaged surgical candidate for interval debulking after 2 cycles of treatment * Patients have adequate hematology, liver and kidney functions * Willing and able to attend the visits, to understand the purpose of the trial and all trial-related procedures * ECOG 0-2 * Written informed consent according to national legal and regulatory requirements prior to any project specific procedures Exclusion Criteria: * ECOG ≥3 * Pregnant or lactating women * Any other malignancy within the last 5 years which has an impact on the prognosis of the patient * Concurrent participation in another clinical trial on the same indication * Any other serious underlying medical, psychiatric, psychological, familial, or geographical condition, which in the judgment of the sponsor-project leader may interfere with the project or affect patient compliance